CoChat

Model‐based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

Open access
Feng, Yan, Masson, Eric, Dai, David, Parker, Susan M., Berman, David, Roy, Amit · 2014 · British Journal of Clinical Pharmacology
Cited by 103

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aim: Ipilimumab is a fully human, monoclonal antibody that blocks cytotoxic T‐lymphocyte antigen‐4. The objective of the present study was to characterize the clinical pharmacology profile of ipilimumab using a population pharmacokinetic (PPK) approach. Methods: The PPK model was developed using 2095 ipilimumab serum concentration values from 499 patients with unresectable stage III or IV melanoma from four phase II studies, with ipilimumab doses ranging from 0.3 to 10 mg kg−1. The structural PK model was determined by developing a base PPK model. The effect of covariates on model parameters was assessed by a full covariate model, which incorporated all pre‐specified covariate‐parameter relationships into the base model. The final model was developed by backward elimination, followed by exclusion of covariates determined not to be of clinical relevance to ipilimumab, and was rigorously validated against both internal and external datasets. Results: Ipilimumab PK was linear and time‐invariant, with dose‐proportional exposures over the available dose range, yielding a terminal half‐life of approximately 15 days. Clearance of ipilimumab increased with increasing body weight and baseline serum lactate dehydrogenase concentrations, but was not affected by age, gender, concomitant budesonide, Eastern Cooperative Oncology Group performance status or prior systemic anticancer therapy. Furthermore, ipilimumab exposure was not affected by moderate renal impairment or mild hepatic impairment. Conclusions: Ipilimumab concentration–time data were well described by a linear, two compartment, zero order i.v. infusion model. The model confirms that a body weight‐normalized dosing regimen is appropriate for ipilimumab therapy in patients with advanced melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.12323

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 103

Metadata

Authors
Feng, Y., Masson, E., Dai, D., Parker, S. M., Berman, D., & Roy, A.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2014-06-20
Volume
78
Issue
1
Pages
106-117
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1950972410
Cited by
103
References
6
FWCI
2.44
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Model‐based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. https://app.cochat.ai/papers/10.1111/bcp.12323
The paper
Feng, Y., Masson, E., Dai, D., Parker, S. M., Berman, D., & Roy, A. (2014). Model‐based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.12323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.